Cansino Biotech (06185) announced that the company plans to sign a “Product Transfer and Technology License Agreement” with Shanghai Pharmaceutical Cansino, approximately...
Zhitong Finance App News, Cansino Biotech (06185) announced that the company plans to sign a “Product Transfer and Technology License Agreement” with Shanghai Pharmaceutical Cansino, agreeing that the company will transfer the recombinant Ebola virus disease vaccine (adenovirus vector) (hereinafter referred to as “transferred product” or “AD5-eBOV”) and the global commercialization rights of the transferred products to Shangyao Kangxino, and will reach commercial cooperation through licensing, so that Shangyao Cansino can enjoy the right to use the licensed technology related to the transferred product on a global scale. Since approval, the transferred products have not generated sales revenue. The total cost of transfer and technology licensing of products transferred under the transfer and licensing agreement is RMB 144.171,000 (tax included).
According to the announcement, AD5-eBoV uses the adenovirus vector technology route. Shangyao Cansino has production capacity related to adenovirus technology vaccines and biological products. The company signed a transfer and licensing agreement with Shanghai Pharmaceutical Cansino, which is conducive to the rational use of resources from all parties. The transaction will not adversely affect the company's normal production and operation and future development plans, and will not affect the interests of shareholders, especially small and medium shareholders.